692 related articles for article (PubMed ID: 16757702)
21. Program-specific cost-effectiveness analysis: breast cancer screening policies for a safety-net program.
Melnikow J; Tancredi DJ; Yang Z; Ritley D; Jiang Y; Slee C; Popova S; Rylett P; Knutson K; Smalley S
Value Health; 2013; 16(6):932-41. PubMed ID: 24041343
[TBL] [Abstract][Full Text] [Related]
22. Swiss Medical Board Mammography screening predictions for Switzerland: importance of time-periods.
de Koning HJ; Heijnsdijk EA
J Med Screen; 2015 Dec; 22(4):201-6. PubMed ID: 26018779
[TBL] [Abstract][Full Text] [Related]
23. Mammography screening: an incremental cost effectiveness analysis of two view versus one view procedures in London.
Bryan S; Brown J; Warren R
J Epidemiol Community Health; 1995 Feb; 49(1):70-8. PubMed ID: 7707010
[TBL] [Abstract][Full Text] [Related]
24. Breast MRI screening for average-risk women: A monte carlo simulation cost-benefit analysis.
Mango VL; Goel A; Mema E; Kwak E; Ha R
J Magn Reson Imaging; 2019 Jun; 49(7):e216-e221. PubMed ID: 30632645
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of screening BRCA1/2 mutation carriers with breast magnetic resonance imaging.
Plevritis SK; Kurian AW; Sigal BM; Daniel BL; Ikeda DM; Stockdale FE; Garber AM
JAMA; 2006 May; 295(20):2374-84. PubMed ID: 16720823
[TBL] [Abstract][Full Text] [Related]
26. Screening for mild thyroid failure at the periodic health examination: a decision and cost-effectiveness analysis.
Danese MD; Powe NR; Sawin CT; Ladenson PW
JAMA; 1996 Jul 24-31; 276(4):285-92. PubMed ID: 8656540
[TBL] [Abstract][Full Text] [Related]
27. Mammography screening for older women with and without cognitive impairment.
Messecar DC
J Gerontol Nurs; 2000 Apr; 26(4):14-24; quiz 52-3. PubMed ID: 11272962
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of the Norwegian breast cancer screening program.
van Luijt PA; Heijnsdijk EA; de Koning HJ
Int J Cancer; 2017 Feb; 140(4):833-840. PubMed ID: 27861849
[TBL] [Abstract][Full Text] [Related]
29. Inefficiencies and High-Value Improvements in U.S. Cervical Cancer Screening Practice: A Cost-Effectiveness Analysis.
Kim JJ; Campos NG; Sy S; Burger EA; Cuzick J; Castle PE; Hunt WC; Waxman A; Wheeler CM;
Ann Intern Med; 2015 Oct; 163(8):589-97. PubMed ID: 26414147
[TBL] [Abstract][Full Text] [Related]
30. The cost-effectiveness of digital breast tomosynthesis in a population breast cancer screening program.
Wang J; Phi XA; Greuter MJW; Daszczuk AM; Feenstra TL; Pijnappel RM; Vermeulen KM; Buls N; Houssami N; Lu W; de Bock GH
Eur Radiol; 2020 Oct; 30(10):5437-5445. PubMed ID: 32382844
[TBL] [Abstract][Full Text] [Related]
31. Cost effectiveness of mammography screening for Chinese women.
Wong IO; Kuntz KM; Cowling BJ; Lam CL; Leung GM
Cancer; 2007 Aug; 110(4):885-95. PubMed ID: 17607668
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of annual versus biennial screening mammography for women with high mammographic breast density.
Pataky R; Ismail Z; Coldman AJ; Elwood M; Gelmon K; Hedden L; Hislop G; Kan L; McCoy B; Olivotto IA; Peacock S
J Med Screen; 2014 Dec; 21(4):180-8. PubMed ID: 25186116
[TBL] [Abstract][Full Text] [Related]
33. Probabilistic cost-effectiveness modeling of different breast cancer screening policies in Slovenia.
Rojnik K; Naversnik K; Mateović-Rojnik T; Primiczakelj M
Value Health; 2008; 11(2):139-48. PubMed ID: 18380626
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriers.
Cott Chubiz JE; Lee JM; Gilmore ME; Kong CY; Lowry KP; Halpern EF; McMahon PM; Ryan PD; Gazelle GS
Cancer; 2013 Mar; 119(6):1266-76. PubMed ID: 23184400
[TBL] [Abstract][Full Text] [Related]
35. Comparative effectiveness of incorporating a hypothetical DCIS prognostic marker into breast cancer screening.
Trentham-Dietz A; Ergun MA; Alagoz O; Stout NK; Gangnon RE; Hampton JM; Dittus K; James TA; Vacek PM; Herschorn SD; Burnside ES; Tosteson ANA; Weaver DL; Sprague BL
Breast Cancer Res Treat; 2018 Feb; 168(1):229-239. PubMed ID: 29185118
[TBL] [Abstract][Full Text] [Related]
36. The Long-Term Effectiveness and Cost Effectiveness of Organized versus Opportunistic Screening for Breast Cancer in Austria.
Schiller-Fruehwirth I; Jahn B; Einzinger P; Zauner G; Urach C; Siebert U
Value Health; 2017 Sep; 20(8):1048-1057. PubMed ID: 28964436
[TBL] [Abstract][Full Text] [Related]
37. Tailoring Breast Cancer Screening Intervals by Breast Density and Risk for Women Aged 50 Years or Older: Collaborative Modeling of Screening Outcomes.
Trentham-Dietz A; Kerlikowske K; Stout NK; Miglioretti DL; Schechter CB; Ergun MA; van den Broek JJ; Alagoz O; Sprague BL; van Ravesteyn NT; Near AM; Gangnon RE; Hampton JM; Chandler Y; de Koning HJ; Mandelblatt JS; Tosteson AN;
Ann Intern Med; 2016 Nov; 165(10):700-712. PubMed ID: 27548583
[TBL] [Abstract][Full Text] [Related]
38. Performance goals for an adjunct diagnostic test to reduce unnecessary biopsies after screening mammography: analysis of costs, benefits, and consequences.
Lee CI; Bensink ME; Berry K; Musa Z; Bodnar C; Dann R; Jarvik JG; Lehman CD; Ramsey SD
J Am Coll Radiol; 2013 Dec; 10(12):924-30. PubMed ID: 24295942
[TBL] [Abstract][Full Text] [Related]
39. Mammography screening: prospects and opportunity costs.
Navarro AM; Kaplan RM
Womens Health; 1996; 2(4):209-33. PubMed ID: 9421557
[TBL] [Abstract][Full Text] [Related]
40. Cost-effectiveness of extending screening mammography guidelines to include women 40 to 49 years of age.
Salzmann P; Kerlikowske K; Phillips K
Ann Intern Med; 1997 Dec; 127(11):955-65. PubMed ID: 9412300
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
